Suvretta Capital Management LLC Cuts Stock Holdings in Sanofi (NASDAQ:SNY)

Suvretta Capital Management LLC cut its position in shares of Sanofi (NASDAQ:SNY) by 17.0% during the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 174,901 shares of the company’s stock after selling 35,800 shares during the period. Suvretta Capital Management LLC’s holdings in Sanofi were worth $10,080,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in SNY. Barrow Hanley Mewhinney & Strauss LLC raised its stake in shares of Sanofi by 113.8% during the 2nd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 5,943,547 shares of the company’s stock worth $288,381,000 after buying an additional 3,164,092 shares during the period. Magnetar Financial LLC increased its holdings in Sanofi by 1,153.1% in the 2nd quarter. Magnetar Financial LLC now owns 2,506,286 shares of the company’s stock worth $121,605,000 after acquiring an additional 2,306,286 shares in the last quarter. Jennison Associates LLC raised its position in Sanofi by 938.0% during the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company’s stock worth $109,753,000 after acquiring an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans lifted its holdings in Sanofi by 28,890.2% during the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company’s stock valued at $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. Finally, Bank of New York Mellon Corp grew its position in shares of Sanofi by 19.0% in the second quarter. Bank of New York Mellon Corp now owns 8,594,740 shares of the company’s stock valued at $417,017,000 after purchasing an additional 1,370,232 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently weighed in on the stock. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com cut Sanofi from a “strong-buy” rating to a “buy” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Sanofi has a consensus rating of “Moderate Buy” and a consensus price target of $57.50.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $48.72 on Friday. The firm has a 50-day simple moving average of $53.17 and a 200-day simple moving average of $52.15. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The stock has a market capitalization of $123.64 billion, a price-to-earnings ratio of 24.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.61. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97.

Sanofi (NASDAQ:SNY) last released its quarterly earnings data on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion during the quarter, compared to the consensus estimate of $16.59 billion. During the same quarter in the prior year, the firm earned $2.55 EPS. Sanofi’s quarterly revenue was up 12.3% on a year-over-year basis. On average, equities analysts predict that Sanofi will post 4.29 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.